公开(公告)号：US12016905B2

公开(公告)日：2024-06-25

申请号：US17108485

申请日：2020-12-01

Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Ki Hoon Ahn ,  Eun Jin Wang

IPC: A61K38/39 ,  A61K31/4439 ,  A61P15/06 ,  C12Q1/6881 ,  G01N33/50 ,  G01N33/68

CPC classification number: A61K38/39 ,  A61K31/4439 ,  A61P15/06 ,  C12Q1/6881 ,  G01N33/5023 ,  G01N33/5044 ,  G01N33/6887 ,  C12Q2600/106

Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of preterm birth, comprising, as an active ingredient, an agent that inhibits the differentiation of fibroblasts into myofibroblasts in cervix.

公开(公告)号：US11969434B1

公开(公告)日：2024-04-30

申请号：US17823080

申请日：2022-08-29

Applicant: Lipocine Inc.

Inventor： Jonathan Ogle ,  Benjamin J. Bruno ,  Kongnara Papangkorn ,  Samuel Akapo ,  Joel Frank ,  Nachiappan Chidambaram ,  Mahesh V. Patel

IPC: A61K31/57 ,  A61K9/00 ,  A61K9/14 ,  A61K31/557 ,  A61P15/06 ,  A61P21/00

CPC classification number: A61K31/57 ,  A61K9/0053 ,  A61K9/14 ,  A61K31/557 ,  A61P15/06 ,  A61P21/00

Abstract: Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability.

公开(公告)号：US20240082261A1

公开(公告)日：2024-03-14

申请号：US18502589

申请日：2023-11-06

Applicant: UNIVERSITY OF SOUTH FLORIDA

Inventor： Charles Lockwood ,  Ozlem Guzeloglu-Kayisli ,  Umit Ali Kayisli ,  Frederick Schatz

IPC: A61K31/557 ,  A61K31/201 ,  A61P15/06

CPC classification number: A61K31/557 ,  A61K31/201 ,  A61P15/06

Abstract: Disclosed are compositions and methods for delaying or preventing idiopathic preterm

公开(公告)号：US11696939B2

公开(公告)日：2023-07-11

申请号：US17138864

申请日：2020-12-30

Applicant: ILIAS Biologics Inc ,  ILIAS Therapeutics, Inc.

Inventor： Chulhee Choi ,  Kyungsun Choi ,  Ramkumar Menon

IPC: A61K35/12 ,  A61K38/17 ,  A61K47/69 ,  A61P15/06 ,  A61K38/095 ,  A61K9/127 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/405 ,  A61K31/43 ,  A61K31/4422 ,  A61K31/545 ,  A61K31/57 ,  A61K31/7048 ,  A61K33/06 ,  A61K38/16 ,  A61K38/45 ,  A61K38/51

CPC classification number: A61K38/1738 ,  A61K9/127 ,  A61K31/137 ,  A61K31/405 ,  A61K31/4025 ,  A61K31/43 ,  A61K31/4422 ,  A61K31/545 ,  A61K31/57 ,  A61K31/7048 ,  A61K33/06 ,  A61K38/095 ,  A61K38/164 ,  A61K38/168 ,  A61K38/1709 ,  A61K38/1774 ,  A61K38/45 ,  A61K38/51 ,  A61K47/6911 ,  A61P15/06

Abstract: The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.

公开(公告)号：US20230101470A1

公开(公告)日：2023-03-30

申请号：US17512365

申请日：2021-10-27

Applicant: Lipocine Inc.

Inventor： Kilyoung Kim ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Benjamin J. Bruno ,  Shadi Mehraban

IPC: A61K31/573 ,  A61K9/00 ,  A61P15/06

Abstract: An HPC composition and method of treatment for the prevention of PTB and improved neonatal outcomes. The invention provides for a dosing regimen beginning as early as 14 weeks of fetal gestation and dosing regimens of a duration of as much as 25 weeks. The invention provides a high level of exogeneous progestin to endogenous progesterone when it is most needed. The instant invention consistently achieves active levels of HPC which achieve effectiveness. Exemplary dosing regimens comprise an oral administration of HPC in the range of 1,200 mg to 1600 mg, wherein the HPC is administered via a once a day, twice a day, or three times a day administration.

公开(公告)号：US11534428B1

公开(公告)日：2022-12-27

申请号：US16411974

申请日：2019-05-14

Applicant: ObsEva S.A.

Inventor： Jean-Pierre Gotteland ,  Oliver Pohl

IPC: A61K31/426 ,  A61P15/06 ,  A61K31/573 ,  A61K31/4422

Abstract: The invention provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks. Using the compositions and methods described herein, such subjects may be administered nifedipine in combination with a prostaglandin F2α (PGF2α) antagonist. Exemplary PGF2α receptor antagonists that may be used for the treatment or prevention of preterm labor as described herein include 1,3-thiazolidine-2-carboxamide compounds, such as (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate hydrochloride. Using the compositions and methods described herein, a subject may be dosed with a PGF2α receptor antagonist and a reduced amount or frequency of nifedipine relative to the amount or frequency of nifedipine that would otherwise be used if the nifedipine were given in the absence of the PGF2α receptor antagonist.

公开(公告)号：US20220347135A1

公开(公告)日：2022-11-03

申请号：US17440178

申请日：2020-03-20

Applicant: The Regents of the University of California ,  The Leland Stanford Junior University

Inventor： Marina Sirota ,  Brian Le ,  Ronald Wong ,  David Stevenson

IPC: A61K31/192 ,  A61K31/573 ,  A61K31/167 ,  A61K31/353 ,  A61K31/19 ,  A61K31/546 ,  A61K31/222 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/438 ,  A61K31/4035 ,  A61K31/43 ,  A61K31/135 ,  A61P15/06

Abstract: Spontaneous preterm birth (sPTB) is premature delivery prior to 37 weeks of pregnancy and is a leading cause of infant mortality worldwide. sPTB is associated with a unique gene expression profile. Identified herein are numerous safe and proven therapeutic compositions used for unrelated indications that have the biological effect of reversing, in part, the gene expression profile of sPTB and which can be used in preventative or interventional treatments to prevent, delay, or ameliorate sPTB. The repurposed drugs include several Class A and Class B therapeutics that are regarded as safe or low risk in pregnant subjects.

公开(公告)号：US20220339176A1

公开(公告)日：2022-10-27

申请号：US17754102

申请日：2020-09-23

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Liang Liang ,  Michael P. Snyder

IPC: A61K31/704 ,  A61K31/573 ,  A61K31/566 ,  A61K31/5685 ,  A61K31/7008 ,  A61K31/4406 ,  A61K31/685 ,  A61P15/06

Abstract: Methods of treatment for menstrual complications, gestational complications, and to prolong gestation are described. Treatments include administration of a compound related to regulation of gestational progress or uterine contractions.

公开(公告)号：US11197868B2

公开(公告)日：2021-12-14

申请号：US16488494

申请日：2018-02-23

Applicant: UNIVERSITY OF SOUTH FLORIDA

Inventor： Charles Lockwood ,  Özlem Guzeloglu-Kayisli ,  Ümit Kayisli ,  Frederick Schatz

IPC: A61K31/5575 ,  A61P15/06

Abstract: The disclosure is directed to a method of enhancing progesterone receptor (PR) activity in a mammal, which comprises administering a composition comprising an inhibitor of FK506 binding protein 51 (FKBP51) to a mammal in need thereof, such as a pregnant human female, whereby progesterone receptor activity in the mammal is enhanced as compared to a mammal not administered the composition. The method results in an extension of the gestation period and a decreased likelihood of preterm birth and fetal growth restriction.

公开(公告)号：US11078264B2

公开(公告)日：2021-08-03

申请号：US16655733

申请日：2019-10-17

Applicant: UNIVERSITY OF CONNECTICUT

Inventor： Christopher Nold ,  Anthony Vella

IPC: C07K16/24 ,  A61P15/06 ,  A61K39/00 ,  A61K38/16 ,  C12N15/113

Abstract: A method of treating a pregnant female subject includes administering to the pregnant female subject an effective amount of a Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) inhibitor, wherein the effective amount of the GM-CSF inhibitor is effective to reduce, prevent or delay preterm birth.